目的 評價喜炎平注射液治療慢性阻塞性肺疾病急性加重期（AECOPD）的療效與安全性。方法 檢索PubMed、EMbase、The Cochrane Library、中國學術期刊全文數(shù)據(jù)庫（CNKI）、中國生物醫(yī)學文獻數(shù)據(jù)庫（CBM）、維普中文期刊全文數(shù)據(jù)庫（VIP）和萬方數(shù)據(jù)庫中發(fā)表的關于喜炎平注射液治療AECOPD的臨床隨機對照試驗（RCT），從建庫起至2020年2月20日，采用Jadad量表對納入的文獻進行質(zhì)量評價，運用RevMan 5.3軟件進行Meta-分析。結(jié)果 共納入19項RCTs，包括1 500例患者。Meta-分析結(jié)果顯示：喜炎平注射液組在總有效率[WMD=3.68，95%CI=（2.68，5.06），P<0.000 01]、呼吸困難的消失時間[WMD=-2.25，95%CI=（-2.53，-1.97），P<0.000 01]、白細胞計數(shù)[WMD=0.95，95%CI=（0.67，1.23），P<0.000 01]、中性粒細胞比值[WMD=3.16，95%CI=（-0.42，6.74），P=0.08]、二氧化碳分壓[WMD=3.76，95%CI=（1.75，5.77），P=0.000 3]、氧分壓[WMD=5.64，95%CI=（4.75，6.52），P<0.000 01]、FEV₁占預計值百分比[WMD=3.46，95%CI=（0.47，6.46），P=0.02]、C反應蛋白[WMD=6.93，95%CI=（4.28，9.58），P<0.000 01]等指標的結(jié)果均優(yōu)于對照組。結(jié)論 臨床治療AECOPD時加用喜炎平注射液可取得更好療效，但本研究所納入的文獻質(zhì)量偏低，需要更多規(guī)范的臨床研究進一步印證。

Objective To evaluate of curative effect of Xiyanping Injection in treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods The randomized controlled trials (RCT) of Xiyanping Injection in the treatment of AECOPD from database establishment to February 20, 2020 were retrieved from PubMed, Embase, Cochrane library, CNKI, CBM, VIP and Wanfang database. Meta-analysis were performed with RevMan 5.3 software. Results A total of 19 RCTs were included, including 1 500 patients. Comparing to control group, Xiyanping Injection showed better therapeutic outcomes regarding to total effective rate[WMD=3.68, 95%CI=(2.68, 5.06), P<0.000 01], the disappearance time of dyspnea symptoms[WMD=-2.25, 95%CI=(-2.53, -1.97), P<0.000 01], white blood cell count[WMD=0.95, 95%CI=(0.67, 1.23), P<0.000 01], neutrophil ratio[WMD=3.16, 95%CI=(-0.42, 6.74), P=0.08], PaCO₂[WMD=3.76, 95%CI=(1.75, 5.77), P=0.0003], PaO₂[WMD=5.64, 95%CI=(4.75, 6.52), P<0.000 01], FEV₁ accounts for The percentage of predicted value[WMD=3.46, 95%CI=(0.47, 6.46), P=0.02], C-reactive protein[WMD=6.93, 95%CI=(4.28, 9.58), P<0.000 01] than Control group. Conclusion In the treatment of AECOPD, Xiyanping Injection can achieve better curative effect, but the quality of the included study is poor, and more high-quality randomized controlled trials are needed to further confirm.

R974;R286.4

國家中醫(yī)藥管理局國家中醫(yī)臨床研究基地業(yè)務建設科研專項課題（JDZX2015200）；廣東省中醫(yī)院中醫(yī)藥科學技術研究專項（YN2015QN10）